Stock A206650 EUBIOLOGICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

EuBiologics Co., Ltd. Share Price

Equities

A206650

KR7206650004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
13,390 KRW -2.69% Intraday chart for EuBiologics Co., Ltd. -1.18% +16.74%
01-29 Zimbabwe launches door-to-door cholera vaccination campaign RE
2023 Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial CI

Financials

Sales 2024 * 116B 83.75M 6.71B Sales 2025 * 128B 92.42M 7.41B Capitalization 489B 353M 28.26B
Net income 2024 * 29B 20.94M 1.68B Net income 2025 * 34B 24.55M 1.97B EV / Sales 2024 * 4.33 x
Net Debt 2024 * 14B 10.11M 810M Net Debt 2025 * 14B 10.11M 810M EV / Sales 2025 * 3.93 x
P/E ratio 2024 *
16.6 x
P/E ratio 2025 *
14.4 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.14%
More Fundamentals * Assessed data

Chart EuBiologics Co., Ltd.

Dynamic Chart

Latest news about EuBiologics Co., Ltd.

Zimbabwe launches door-to-door cholera vaccination campaign RE
Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial CI
EuBiologics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South Korea CI
Clips Co., Ltd. announced that it expects to receive KRW 2.50003 billion in funding from EuBiologics Co., Ltd., SK bioscience Co.,Ltd., BNC Korea Co., Ltd. CI
SK bioscience : S.Korea to begin producing Novavax COVID-19 vaccine as early as June RE
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea CI
EuBiologics Co., Ltd.(KOSDAQ:A206650) added to S&P Global BMI Index CI
ATGC Co., Ltd. announced that it has received KRW 2.1 billion in funding from EuBiologics Co., Ltd. CI
ATGC Co., Ltd. announced that it expects to receive KRW 2.1 billion in funding from EuBiologics Co., Ltd. CI
EuBiologics Co., Ltd. announced that it has received KRW 30.00000351 billion in funding CI
EuBiologics Co., Ltd. announced that it expects to receive KRW 30 billion in funding CI
Global Health Investment Fund I, LLC, managed by Global Health Investment Advisors, LLC acquired 6.19% stake in EuBiologics Co., Ltd.. CI
EuBiologics Co., Ltd. has completed an IPO in the amount of KRW 19.2 billion. CI
EuBiologics Co., Ltd. has filed an IPO. CI
More news

Press releases EuBiologics Co., Ltd.

Gavi and UNICEF welcome approval of new oral cholera vaccine AQ
Gavi and Unicef Welcome Approval of New Oral Cholera Vaccine [press release] AQ
What's Behind the Worldwide Shortage of Cholera Vaccines? for Starters, They're Only Made By One Company [analysis] AQ
Gavi - Global vaccine alliance outlines path to sustainable cholera vaccine supply AQ
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19 AQ
More press releases

News in other languages on EuBiologics Co., Ltd.

Reservas de vacunas contra el cólera, "vacías" ante aumento de casos
More news

Quotes and Performance

1 day-2.69%
1 week-1.18%
Current month+10.48%
1 month+10.48%
3 months+23.18%
6 months+44.60%
Current year+16.74%
More quotes

Highs and lows

1 week
13 070.00
Extreme 13070
14 340.00
1 month
11 490.00
Extreme 11490
14 500.00
Current year
10 060.00
Extreme 10060
14 500.00
1 year
6 260.00
Extreme 6260
14 500.00
3 years
6 260.00
Extreme 6260
61 500.00
5 years
4 655.00
Extreme 4655
61 500.00
10 years
3 650.00
Extreme 3650
61 500.00
More quotes

Managers and Directors - EuBiologics Co., Ltd.

Managers TitleAgeSince
Yeong-Ok Baek CEO
 Chief Executive Officer 61 31/12/04
Suk-Keun Choi DFI
 Director of Finance/CFO 57 31/07/10
Kyeong-Ho Min BRD
 Director/Board Member 55 30/11/10
Members of the board TitleAgeSince
Suk-Keun Choi DFI
 Director of Finance/CFO 57 31/07/10
Yeong-Ok Baek CEO
 Chief Executive Officer 61 31/12/04
Kyeong-Ho Min BRD
 Director/Board Member 55 30/11/10
More insiders

Quotes

Date Price Change Volume
30/04/24 13,390 -2.69% 385,803
29/04/24 13,760 -1.08% 424,525
26/04/24 13,910 +0.58% 859,800
25/04/24 13,830 +2.90% 681,143
24/04/24 13,440 -1.18% 538,128

End-of-day quote Korea S.E., April 29, 2024

More quotes

Company Profile

EuBiologics Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of biopharmaceuticals. The Company operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.
Sector
Pharmaceuticals
Calendar
09/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
EUBIOLOGICS CO., LTD. Stock EuBiologics Co., Ltd.
+16.74% 353M
CSL LIMITED Stock CSL Limited
-4.24% 86.85B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.16B
BIOGEN INC. Stock Biogen Inc.
-16.21% 31.28B
UCB Stock UCB
+57.86% 25.27B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.58% 15.33B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.89% 8.83B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-10.53% 7.94B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A206650 Stock